Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report
ConclusionsDurvalumab plus tremelimumab combination therapy can lead to fulminant immune-mediated myocarditis. This patient's myocarditis was amenable to treatment with high-dose intravenous steroids and mycophenolate.
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research
More News: Cancer | Cancer & Oncology | Cardiology | CT Scan | Endometrial Cancer | Heart | Laboratory Medicine | Myocarditis | PET Scan